SGMO
Closed
Sangamo Therapeutics Inc
0.5362
-0.0051 (-0.94%)
Last Update: 01 Jul 2025 23:28:00
Yesterday: 0.5413
Day's Range: 0.5118 - 0.55
Send
sign up or login to leave a comment!
When Written:
1.49
Sangamo Therapeutics Inc. is a clinical stage biotechnology company that specializes in developing genomic therapies to treat various genetic diseases. The company was founded in 1995 and is headquartered in Richmond, California, USA. Sangamo's primary focus is on developing gene-editing therapies that can modify a patient's DNA to treat genetic disorders. The company's technology platform is based on the use of zinc finger proteins, which are naturally occurring proteins that can be engineered to target specific genes. Sangamo's lead product candidate is SB-525, a gene therapy for hemophilia A, which is currently in Phase 3 clinical trials. The company has also developed gene-editing therapies for sickle cell disease, beta-thalassemia, and other genetic disorders. Sangamo has partnerships with several pharmaceutical companies, including Pfizer and Sanofi, to develop gene therapies for various diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








